Design of multivalent ligand targeting G-protein-coupled receptors.

Abstract:

:More and more evidences are still accumulating rapidly on the G-protein-coupled-receptors (GPCRs) dimerization/oligomerization. Such common feature of GPCRs has called extensive attention to both pharmacologists and medicinal chemists for illustration of the pharmacological functions and therapeutic utilities of such receptor complex. Although there is still no clear explanation for the receptor dimerization/oligomerization, a large number of multivalent ligands (MLs) have been designed to target the receptor-dimers/oligomers. Such MLs have gained much acceptance in exploring the receptor complex of dopaminergic, adrenergic, serotoninergic, and opioidic receptor systems, due to the relatively broader experience in recognizing the receptor-dimerization. More and more MLs have also been designed to face GPCR-related very complex neurodegenerative diseases, such as Parkinson's disease (PD), Alzheimer's disease (AD) and schizophrenia, which are not effectively treated by traditional highly selective drugs. Herein, some of the most recent developments in this field, as well as some typical examples of MLs, are highlighted, with a particular focus on GPCRs.

journal_name

Curr Pharm Des

authors

Liu Z,Zhang J,Zhang A

doi

10.2174/138161209787315639

subject

Has Abstract

pub_date

2009-01-01 00:00:00

pages

682-718

issue

6

eissn

1381-6128

issn

1873-4286

journal_volume

15

pub_type

杂志文章,评审
  • Retinol-binding protein 4 and new adipocytokines in nonalcoholic fatty liver disease.

    abstract::Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent causes of hepatic dysfunction and is highly correlated with components of the metabolic syndrome such as obesity, insulin resistance and type 2 diabetes. Among others, nutritional factors, physical inactivity, genetic variants and visceral obesity h...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161210791208938

    authors: Tönjes A,Blüher M,Stumvoll M

    更新日期:2010-06-01 00:00:00

  • Synergistic effect of inhibitors of MMPs and ROS-dependent modifications of contractile proteins on protection hearts subjected to oxidative stress.

    abstract::Cardiac ischemia, followed by reperfusion, often results in the development of cardiac contractile dysfunction that limits the recovery prognosis of patients. The current goal of pharmacological therapy in the course of ischemic heart disease is to improve the oxygen supply/demand ratio for the heart. Cardiac contract...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/13816128113199990556

    authors: Sawicki G

    更新日期:2014-01-01 00:00:00

  • Actions of selected cardiovascular hormones on arterial stiffness and wave reflections.

    abstract::The large conduit arteries of the thorax and abdomen are elastic while those in the arms and legs are muscular. Alterations in wall properties of elastic arteries occur over time and are usually permanent in nature; acute changes can, however, occur is response to a change in transmural pressure. Chronic alterations i...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161209787354258

    authors: Nichols WW,Epstein BJ

    更新日期:2009-01-01 00:00:00

  • A Peptide Construct Mediates Focal Adhesion Pathway Through the Activation of Integrin Receptor.

    abstract:BACKGROUND:The integrin family receptors stimulate the cellular proliferation and migration through the focal adhesion pathway by the activation of PTK2, VASP and TSP1 proteins. The purpose of this study was to investigate the integrin-ligated motifs through the activation of focal adhesion pathway. METHODS:A chimeric...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章

    doi:10.2174/1381612826666200311125325

    authors: Khosravi M,Kakavandi N,Rezaee S,Shabani M,Najafi M

    更新日期:2020-01-01 00:00:00

  • Targeting IL-23 and Th17-cytokines in inflammatory bowel diseases.

    abstract::Over the last 15 years, the use of various biological therapies has largely improved the way we manage patients with Inflammatory Bowel Diseases (IBDs). Blockade of cytokine synthesis and/or activity is at the forefront of this new era with the success of inhibitors of tumor necrosis factor (TNF)-α. These therapies ar...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161210794079164

    authors: De Nitto D,Sarra M,Cupi ML,Pallone F,Monteleone G

    更新日期:2010-01-01 00:00:00

  • Natural Antioxidants, Health Effects and Bioactive Properties of Wild Allium Species.

    abstract:BACKGROUND:There is an increasing interest from the pharmaceutical and food industry in natural antioxidant and bioactive compounds derived from plants as substitutes for synthetic compounds. The genus Allium is one of the largest genera, with more than 900 species, including important cultivated and wild species, havi...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612826666200203145851

    authors: Petropoulos SA,Di Gioia F,Polyzos N,Tzortzakis N

    更新日期:2020-01-01 00:00:00

  • Topical delivery of drugs for the effective treatment of fungal infections of skin.

    abstract::The prevalence of fungal infections of skin has increased rapidly, affecting approximately 40 million people across the globe. A wide variety of antifungal drugs has been utilized in the effective management of numerous dermatological infections. Topical treatment of fungal infections has proved to be quite advantageo...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612821666150428150456

    authors: Akhtar N,Verma A,Pathak K

    更新日期:2015-01-01 00:00:00

  • Inflammatory cytokines, growth factors, and depression.

    abstract::There is a plausible role for cytokines, brain-derived neurotrophic factor (BDNF), and their interaction in major depressive disorder's (MDD) etiology. This review includes (i) briefly defining cytokines, (ii) a discussion of theories for why they may affect brain function, (iii) cross-sectional associations between c...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161212803523680

    authors: Lotrich F

    更新日期:2012-01-01 00:00:00

  • Journey to the Center of the Cell: Current Nanocarrier Design Strategies Targeting Biopharmaceuticals to the Cytoplasm and Nucleus.

    abstract::New biopharmaceutical molecules, potentially able to provide more personalized and effective treatments, are being identified through the advent of advanced synthetic biology strategies, sophisticated chemical synthesis approaches, and new analytical methods to assess biological potency. However, translation of many o...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612822666151216151420

    authors: Munsell EV,Ross NL,Sullivan MO

    更新日期:2016-01-01 00:00:00

  • BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing.

    abstract::Commonly, the angiogenic growth factors signify healing. However, gastrointestinal ulceration is still poorly understood particularly with respect to a general pharmacological/pathophysiological role of various angiogenic growth factors implemented in growth factors wound healing concept. Thereby, we focused on the st...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612824666180712110447

    authors: Seiwerth S,Rucman R,Turkovic B,Sever M,Klicek R,Radic B,Drmic D,Stupnisek M,Misic M,Vuletic LB,Pavlov KH,Barisic I,Kokot A,Japjec M,Blagaic AB,Tvrdeic A,Rokotov DS,Vrcic H,Staresinic M,Sebecic B,Sikiric P

    更新日期:2018-01-01 00:00:00

  • Selective inhibitors of zinc-dependent histone deacetylases. Therapeutic targets relevant to cancer.

    abstract::Histone deacetylases (HDACs), which act on acetylated histones and/or other non-histone protein substrates, represent validated epigenetic targets for the treatment of cancer and other human diseases. The inhibition of HDAC activity was shown to induce cell cycle arrest, differentiation, apoptosis as well as a decreas...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612820666141110164604

    authors: Kollar J,Frecer V

    更新日期:2015-01-01 00:00:00

  • Clinical experience with specific COX-2 inhibitors in arthritis.

    abstract::The common mechanism of action of aspirin and the chemically unrelated non-steroidal anti-inflammatory drugs (NSAIDs) is the inhibition of prostaglandin (PG) production due to interference with the enzymatic activity of cyclooxygenase (COX). These agents have long been used as effective treatments for arthritis. The r...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612003398753

    authors: Crofford LJ

    更新日期:2000-11-01 00:00:00

  • High-density lipoprotein-mediated anti-atherosclerotic and endothelial-protective effects: a potential novel therapeutic target in cardiovascular disease.

    abstract::Reduced levels of high-density lipoprotein cholesterol (HDL) are associated with a substantially increased risk of coronary disease and cardiovascular events. Furthermore, numerous studies have suggested that HDL may exert several potentially important antiatherosclerotic and endothelial-protective effects. In particu...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161210791051013

    authors: Besler C,Heinrich K,Riwanto M,Lüscher TF,Landmesser U

    更新日期:2010-05-01 00:00:00

  • Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression.

    abstract::Agomelatine markedly differs from other classes of antidepressant drugs: its primary molecular targets in vivo are the melatonin MT(1) and MT(2) receptors, where it acts as a potent agonist, and the 5-HT(2C) receptors, where it exerts clear-cut antagonist properties. Agomelatine across a wide range of clinical trials ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161209788168056

    authors: Bourin M,Prica C

    更新日期:2009-01-01 00:00:00

  • Pharmacological Treatments for Fragile X Syndrome Based on Synaptic Dysfunction.

    abstract:BACKGROUND:Fragile X syndrome (FXS) is the most common form of monogenic hereditary cognitive impairment, including intellectual disability, autism, hyperactivity, and epilepsy. METHODS:This article reviews the literature pertaining to the role of synaptic dysfunction in FXS. RESULTS:In FXS, synaptic dysfunction alte...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612825666191102165206

    authors: Telias M

    更新日期:2019-01-01 00:00:00

  • Systematic Development and Optimization of an in-situ Gelling System for Moxifloxacin Ocular Nanosuspension using High-pressure Homogenization with an Improved Encapsulation Efficiency.

    abstract:BACKGROUND:The objective of this study was to apply Quality by Design (QbD) principles on process parameter optimization for the development of hybrid delivery system (combination of (SLNs) and In-situ gelling system) for hydrophilic drug Moxifloxacin Hydrochloride (MOX) to achieve its controlled delivery, which otherw...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章

    doi:10.2174/1381612824666180403115106

    authors: Khurana LK,Singh R,Singh H,Sharma M

    更新日期:2018-01-01 00:00:00

  • Compartmentalized and internally structured particles for drug delivery--a review.

    abstract::Recent advances in the fabrication, characterization and application of micro- and nano-particles that possess a non-uniform internal structure are reviewed. The particle structures include core-shell particles, particles with multiple cores or a multi-layered structure, porous particles with both regular and random p...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612811319350007

    authors: Čejková J,Štêpánek F

    更新日期:2013-01-01 00:00:00

  • PCSK9 inhibitors for the management of dyslipidemia in people with Type 2 Diabetes: How low is too low?

    abstract::Diabetic patients are considered as high risk for development of atherosclerotic disease. Cholesterol treatment is of paramount importance in order to optimise cardiovascular outcomes in this subset of patients. Although statins are regarded as the mainstay of treatment, these may not be tolerated or as efficacious as...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章

    doi:10.2174/1381612826666200617170252

    authors: Felekos I,Karamasis GV,Pavlidis AN

    更新日期:2020-06-17 00:00:00

  • Lipid management for the prevention of cardiovascular disease.

    abstract::Lowering low density lipoprotein (LDL) - cholesterol is one of the key issues in modern preventive cardiology by which we are able to interact with the natural course of atherosclerosis. Diet and healthy life style are mandatory for the treatment of CAD high risk patients. Numerous lipid lowering trials confirmed the ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161211795428849

    authors: Schaefer JR

    更新日期:2011-01-01 00:00:00

  • Carnitine palmitoyltransferase: a viable target for the treatment of NIDDM?

    abstract::Inhibition of fatty acid oxidation is well recognized as a potentially effective mechanism for controlling glycemia in non-insulin-dependent diabetes mellitus (NIDDM). However, a direct targeting of inhibition of the intramitochondrial beta-oxidation pathway or an indirect modulation of fatty acid oxidation by inhibit...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:

    authors: Anderson RC

    更新日期:1998-02-01 00:00:00

  • Runx2/Cbfa1: a multifunctional regulator of bone formation.

    abstract::Runx2/Cbfa/AML3 is a member of the runt homology domain family of transcription factors, essential for osteoblast differentiation and bone formation. Defining the molecular mechanisms by which Runx2 can function as a master regulatory gene for activating the program of osteoblastogenesis has provided novel insights fo...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612033453659

    authors: Lian JB,Stein GS

    更新日期:2003-01-01 00:00:00

  • Molecular mapping in the CNS.

    abstract::Since ancient times the operation of the brain has elicited more than usual interest. Data mining of the human genome is revealing that many CNS abnormalities have a genetic component. As yet this information can not be used directly to cure or ameliorate specific CNS disorders although this is regarded as having grea...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612023394250

    authors: Wong MG,Tehan BG,Lloyd EJ

    更新日期:2002-01-01 00:00:00

  • CD164 as a Basophil Activation Marker.

    abstract::Introduction of flow cytometric technique to the research on basophil activation has led to significant achievements in allergy diagnosis in vitro. Most of the studies employing the flow cytometry used CD63 as a marker of basophil activation and only some of them used CD203c. Recently discovered basophil activation ma...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161211798357890

    authors: Wolanczyk-Medrala A,Barg W,Medrala W

    更新日期:2011-11-01 00:00:00

  • Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering?

    abstract::Type 2 diabetes is associated with substantially increased cardiovascular mortality. The need to reduce the progression of atherosclerosis alongside lowering blood glucose levels is now well established. Ideally, pharmaceutical treatment should address both of these needs. This review summarises current evidence of th...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161209789057995

    authors: Papanas N,Maltezos E

    更新日期:2009-01-01 00:00:00

  • Treatment of hypertensive complications in pregnancy.

    abstract::Hypertension is the most common medical disorder during pregnancy. Approximately 70 percent of women diagnosed with hypertension during pregnancy will have gestational hypertension-preeclampsia. The term gestational hypertension-preeclampsia is used to describe a wide spectrum of patients who may have only mild elevat...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612053381864

    authors: Coppage KH,Sibai BM

    更新日期:2005-01-01 00:00:00

  • Lone atrial fibrillation - a diagnosis of exclusion.

    abstract::Atrial fibrillation (AF) is the most common sustained rhythm disturbance, increasing prevalence with age, in particular in patients with cardiovascular disease. On the other hand, a subset of patients with AF being <60 years old and no evidence of underlying cardiovascular disease, and laboratory tests including thyro...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612820666140825142206

    authors: Tello-Montoliu A,Hernández-Romero D,Sanchez-Martínez M,Valdes M,Marín F

    更新日期:2015-01-01 00:00:00

  • Phosphodiesterase type 5 inhibitors: molecular pharmacology and interactions with other phosphodiesterases.

    abstract::Erectile function is determined by tight regulation of relaxation or contraction of corpus cavernosal smooth muscle, which is the result of a long and complex chain of molecular events. Control of erectile function resides in signaling pathways of the central and peripheral nervous system, as well as intracellular eve...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161205774913426

    authors: Seftel AD

    更新日期:2005-01-01 00:00:00

  • Novel and Practical Approaches to Manage Diet-induced Metabolic Disorders: Part-I.

    abstract::Metabolic syndrome (MetS) which is caused by poor dietary habits and sedentary behavior is a serious global health problem. MetS is a cluster of risk factors, represented by central obesity, hyperglycemia, dyslipidemia, and hypertension. In the 21st century, MetS and associated comorbidities, including obesity, diabet...

    journal_title:Current pharmaceutical design

    pub_type: 社论

    doi:10.2174/138161282639201110165712

    authors: Korivi M,Liu BR

    更新日期:2020-01-01 00:00:00

  • Ligand Conjugated Targeted Nanotherapeutics for Treatment of Neurological Disorders.

    abstract:BACKGROUND:Human brain is amongst the most complex organs in human body, and delivery of therapeutic agents across the brain is a tedious task. Existence of blood brain barrier (BBB) protects the brain from invasion of undesirable substances; therefore it hinders the transport of various drugs used for the treatment of...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612826666200417141600

    authors: Mittal S,Ashhar MU,Qizilbash FF,Qamar Z,Narang JK,Kumar S,Ali J,Baboota S

    更新日期:2020-01-01 00:00:00

  • Cardiac applications for human pluripotent stem cells.

    abstract::Human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs) can self-renew indefinitely, while maintaining the capacity to differentiate into useful somatic cell types, including cardiomyocytes. As such, these stem cell types represent an essentially inexhaustible source of committed human cardiomyo...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161209788923804

    authors: Shiba Y,Hauch KD,Laflamme MA

    更新日期:2009-01-01 00:00:00